Latest Conference Articles

ICON-1 plus ranibizumab effectively reduced CNV size and led to complete drying of the retina for some patients with wet AMD.

Intravitreal bevacizumab effectively lowered the risk of retinal detachment recurrence after primary pars plana vitrectomy.

Patients treated with C3F8 saw a superlative 84% release rate, according to study authors.

Human antibody may substantially reduce need for insulin in patients with T1D.

ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

Boys who are overweight as children but normalize as young adults have the same risk of type 2 diabetes as men who were never overweight.

More than 3,000 original research presentations will be offered in a robust 5-day program.

BMS-986168 significantly reduces CSF free eTau.

An Italian team presented its research on the topic at the 2017 International Congress of Parkinson’s Disease & Movement Disorders Conference.

Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

Dr. Kiki Chang sits down with MD Magazine and talks about the latest data on lurasidone.

Leading eating disorder expert Evelyn Attia, MD, sat down with MD Mag at the American Psychiatric Association meeting to talk about the correlation between obesity and eating disorders.

He and a Danish team believe they've found the cause of multiple sclerosis.

The Mount Sinai Hospital neurology professor shares his thoughts on MS care.

The study presented at CMSC 2017 compared the treatments to an interferon.

Telepsychiatry shown to be viable alternative in rural areas with limited access.

Stephen Krieger, MD, an associate professor at Mount Sinai Hospital, discusses the impact that recently-approved drug ocrelizumab has on the state of multiple sclerosis care, as well as his patient-centered app that depicts the MS condition in a more accurate manner, at the 2017 Consortium of Multiple Sclerosis Centers in New Orleans.

Physicians debated whether they would prescribe the new MS drug to a patient.

Allen Bowling, MD, PhD, physician associate of the Colorado Neurological Institute, discussed widely-researched benefits of cannabis on MS effects, its shortcomings, and the broad outcomes of alternative treatment.

Clyde Markowitz, MD, director of the MS Center at the University of Pennsylvania, discusses how the patterns of male-to-female ratio in MS diagnoses may be linked to hormones, and whether testosterone could be key in bettering treatment.

An overview of the newest treatment options for the disease.

Transcranial Magnetic Stimulation (TMS) is getting good results as an adjunctive therapy for patients with major depression who have failed on several antidepressant medications.

Dr. Melissa Arbuckle explains what neuroscience is and why every practicing psychiatrist should have an understanding and appreciation for this branch of science.

Physicians received an overview of the scope and severity of the disease.

Dr. Stanley Caroff, Emeritus Professor CE of Psychiatry at the Philadelphia VA Medical Center, sits down with MD Magazine to explain what tardive dyskinesia is, and why it's so important for psychiatrists to be aware of this side effect in their patients taking antipsychotic medications. This is the conclusion of a two-part conversation.

Michael Wechsler, MD, MMSc, recounts the phase III trial of Mepolizumab on patients with eosinophilic granulomatosis with polyangiitis (EGPA).

The APA lecture focused on a model with detail to game theory.

Study examined the impact of incidents of adversity experienced in childhood.